Elosulfase Alfa comment watch save
BreastfeedingPediatric

  • TRADE NAME: Vimizim (BioMarin)
  • INDICATIONS: Mucopolysaccharidosis IVA (Morquio A syndrome)
  • CLASS: Enzyme
  • HALF-LIFE: 8–36 minutes
  • FDA APPROVAL DATE: 02/14/2014
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    None known

RISK OF ANAPHYLAXIS

See full prescribing information for complete boxed warning.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top